Intramammary Gel Bacteriophage Delivery for Dairy Cattle Mastitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating mastitis in dairy cattle, primarily caused by Staphylococcus aureus and Escherichia coli, face challenges such as antibiotic resistance, inefficacy against biofilms, and difficulties in delivering bacteriophages effectively to the target site, leading to suboptimal treatment outcomes.
Innovation Solution
A bacteriophage preparation in the form of a gel, using iota-carrageenan as a carrier, is developed for intramammary administration, containing a specific cocktail of bacteriophages (303Ecol101PP, 308Ecol101PP, 310Ecol104PP, 348Ecol098PP, 241Ecol014PP, 351Saur083PP, and 357Saur119PP) to target and lyse pathogenic bacteria, including those forming biofilms, while maintaining stability and activity for at least 12 months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat mastitis, then bacterial infections can be controlled, but antibiotic-resistant bacteria strains develop
Solution Approach 1:
The patent changes the therapeutic agent from antibiotics to bacteriophages, fundamentally altering the treatment parameter. Bacteriophages are viruses that specifically infect and lyse bacteria, providing an alternative mechanism of action that does not select for antibiotic resistance while maintaining treatment efficacy against mastitis-causing bacteria
Solution Approach 2:
The patent introduces bacteriophages as an intermediary substance to deliver the therapeutic effect. Instead of using antibiotics that directly inhibit bacterial growth, bacteriophages act as biological mediators that selectively infect and destroy target bacteria through their natural lytic cycle, bypassing antibiotic resistance mechanisms
2Object-affected harmful factors
If bacteriophages are administered to treat mastitis, then antibiotic resistance is avoided, but delivery effectiveness to the target site is reduced
Solution Approach 1:
The patent applies local quality by formulating bacteriophages in a gel carrier specifically designed for intramammary administration. This localized delivery system ensures high concentration of bacteriophages is deposited directly in the mammary gland tissue where infection occurs, overcoming the challenge of effective delivery to the target site
Solution Approach 2:
The patent introduces a gel carrier as an intermediary substance to facilitate bacteriophage delivery. The gel acts as a vehicle that protects bacteriophages during administration and enables sustained release at the target site, improving delivery effectiveness without compromising the antibiotic-free therapeutic mechanism
3Adaptability or versatility
If bacteriophages are used to target bacteria, then specificity is improved, but stability and activity retention over time is reduced
Solution Approach 1:
The patent uses a gel carrier as an intermediary protective matrix that shields bacteriophages from environmental degradation. The gel formulation maintains bacteriophage stability and activity over extended storage periods (at least 12 months) while preserving their specific lytic properties against target bacteria
Solution Approach 2:
The patent changes the physical state and formulation parameters of bacteriophages by incorporating them into a gel matrix. This formulation approach alters the stability parameters of bacteriophages, enabling long-term storage and shelf-life extension while maintaining their biological activity and host-specific recognition capabilities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gel-based bacteriophage preparation effectively reduces bacterial counts, inhibits biofilm formation, and improves milk quality by selectively targeting and lysing E. coli and S. aureus strains, demonstrating high lytic activity and specificity, with efficacy exceeding 30% in collagen matrix models and 21.6-30.6% reduction in bacterial growth in milk.
Implementation Method 1
A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle... containing a specific cocktail of bacteriophages to target and lyse pathogenic bacteria
Data Source
AI summary
A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, including but not limited to infections caused by E. coli and/or S. aureus, intended for intramammary administration during lactation or dry period, in particular, to treat or prevent mastitis in dairy cattle, its manufacturing method and bacteriophage strains especially useful for such preparation manufacturing, characterised in detail in the enclosed patent claims, was revealed.